X4 Pharmaceuticals, Inc. (XFOR)
| Market Cap | 437.64M +4,685.0% |
| Revenue (ttm) | 15.85M -51.6% |
| Net Income | -90.14M |
| EPS | -0.89 |
| Shares Out | 94.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,597,330 |
| Open | 4.260 |
| Previous Close | 4.170 |
| Day's Range | 4.215 - 4.820 |
| 52-Week Range | 1.350 - 4.830 |
| Beta | 0.39 |
| Analysts | Strong Buy |
| Price Target | 11.60 (+150.0%) |
| Earnings Date | Aug 6, 2026 |
About XFOR
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Ta... [Read more]
Financial Performance
In 2025, X4 Pharmaceuticals's revenue was $35.11 million, an increase of 1273.21% compared to the previous year's $2.56 million. Losses were -$79.20 million, 111.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price target is $11.6, which is an increase of 150.00% from the latest price.
News
X4 Pharmaceuticals reports Q2 EPS (13c), consensus (18c)
Reports Q2 revenue $8.81M, consensus $2.42M. “Since we began leading X4 last August, we have taken meaningful actions to strengthen the execution of the mavorixafor Phase 3 4WARD trial in…
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today reported financial results for the ...
X4 Pharmaceuticals Quarterly report: Q2 2026
X4 Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
X4 Pharmaceuticals Earnings release: Q2 2026
X4 Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 3...
X4 Pharmaceuticals initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of X4 Pharmaceuticals (XFOR) with an Overweight rating and $11 price target The firm believes the Street is materially underestimating the probability of Phase 3 success...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on July 6...
X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board
X4 Pharmaceuticals (XFOR) announced the appointment of Kelly Gold to the company’s board of directors effective July 1, adding strong strategic and financial expertise. Gold will serve as an independe...
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly ...
X4 Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Significant restructuring and capital raises have positioned the company to advance mavorixafor, an oral therapy for chronic neutropenia, through a pivotal phase III trial with data expected in 2027 and potential FDA approval in 2028. The company targets a 15,000-patient U.S. market and plans to explore additional indications after 2028.
X4 Pharmaceuticals initiated with an Outperform at Leerink
Leerink analyst Thomas Smith initiated coverage of X4 Pharmaceuticals (XFOR) with an Outperform rating and $12 price target The firm has a positive view of X4’s lead program mavorixafor, saying…
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that management will prese...
X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c)
Reports Q1 revenue $2.71M, consensus $3.2M. “Our top priority remains the execution and full enrollment of the pivotal 4WARD Phase 3 trial of mavorixafor in chronic neutropenia,” said Adam Craig,…
X4 Pharmaceuticals files $300M mixed securities shelf
16:12 EDT X4 Pharmaceuticals (XFOR) files $300M mixed securities shelf
X4 Pharmaceuticals Registration statement: Registration filing
X4 Pharmaceuticals filed a registration statement on May 6, 2026, providing details about a securities offering with the SEC.
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 - - European Commission Approval of XOLREMDI® (Mavorixafor) Provides the First and Only Authorize...
X4 Pharmaceuticals Quarterly report: Q1 2026
X4 Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
X4 Pharmaceuticals Earnings release: Q1 2026
X4 Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
X4 Pharmaceuticals announces EC approval of Xolremdi
X4 Pharmaceuticals (XFOR) announced that the European Commission has granted marketing authorization for Xolremdi capsules for the treatment of patients with WHIM syndrome in the European Union. “The ...
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia - BOSTON, April 29, ...
X4 Pharmaceuticals Proxy statement: Proxy filing
X4 Pharmaceuticals filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
X4 Pharmaceuticals Proxy statement: Proxy filing
X4 Pharmaceuticals filed a proxy statement on March 20, 2026, providing details for shareholder voting and corporate governance matters.
X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c)
Reports Q4 revenue $2.6M, consensus $1.73M. “Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with…
X4 Pharmaceuticals sees cash runway through 2028
Cash, cash equivalents and short-term investments totaled $253.0 million as of December 31, 2025, which management believes will enable the Company to fund its operations through 2028. Published first...
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive Opinion from European Medicines Agency Recommending Marketing Authorization of Mavorixafor for ...